Beyond PD-1: Roche Maps Further Checkpoints On Cancer Immune Cycle
Executive Summary
Roche gave updates on its immunotherapy research at ASCO, setting the stage for an ambitious slate of combination trials with the company's PD-L1 inhibitor atezolizumab.
You may also be interested in...
Lessons Learned In Immuno-Oncology From Former Roche Exec Dan Chen
In an audio interview from the recent ASCO-SITC meeting, Chen weighs in on comparisons of PD-1 and PD-L1 inhibitors, the IDO failures, biomarkers and his new work at the private biotech IGM Biosciences.
Roche Pushes The Boundaries Of Cancer Immunotherapy
Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.
Roche’s Immuno-Oncology Arsenal: PD-L1 And Beyond
Roche 
may be playing catch-up to Bristol-Myers Squibb and Merck & Co in the PD-1/PD-L1 checkpoint development space, but it believes its unique in-house strengths in diagnostics and molecular biology, coupled with partnering, will enable it to play a major role in immuno-oncology.